Apollomics Inc Ordinary Shares - Class A APLM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APLM is a good fit for your portfolio.
News
-
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
-
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
-
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
-
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
-
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $0.47
- Day Range
- $0.43–0.49
- 52-Week Range
- $0.40–6.45
- Bid/Ask
- $0.45 / $0.45
- Market Cap
- $40.27 Mil
- Volume/Avg
- 245,270 / 206,692
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 45
- Website
- https://www.apollomicsinc.com
Comparables
Valuation
|
Metric
|
APLM
|
09969
|
06628
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.35 | 1.04 | 0.77 |
Price/Sales | — | 9.19 | 12.16 |
Price/Cash Flow | — | — | — |
Price/Earnings
APLM
09969
06628
Financial Strength
|
Metric
|
APLM
|
09969
|
06628
|
|---|---|---|---|
Quick Ratio | 2.82 | 4.18 | 1.50 |
Current Ratio | 2.95 | 4.42 | 1.61 |
Interest Coverage | −1,154.63 | — | −33.53 |
Quick Ratio
APLM
09969
06628
Profitability
|
Metric
|
APLM
|
09969
|
06628
|
|---|---|---|---|
Return on Assets (Normalized) | −123.31% | −4.86% | −22.79% |
Return on Equity (Normalized) | — | −6.87% | −38.31% |
Return on Invested Capital (Normalized) | — | −7.72% | −26.22% |
Return on Assets
APLM
09969
06628
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wbnsdpnt | Gzbmh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ffkpcphwc | Ptmkn | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hsnnyqppn | Jlkxzfd | $97.8 Bil | |
MRNA
| Moderna Inc | Zmvkqzrc | Xcq | $41.3 Bil | |
ARGX
| argenx SE ADR | Cwtptphc | Flnfz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ggsltckc | Dfk | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rjwfzjqt | Lxpyhl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fxkmtvzvt | Lmvnz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pxxxqdfkj | Zwsnmmt | $12.5 Bil | |
INCY
| Incyte Corp | Jptrvwr | Zjvcqgw | $11.6 Bil |